<DOC>
	<DOCNO>NCT01330030</DOCNO>
	<brief_summary>Relapse smoking common problem affect smoker seek treatment . The purpose study examine whether selegiline , give form skin patch , effective stop smoking .</brief_summary>
	<brief_title>Selegiline Patch Treatment Nicotine Dependence</brief_title>
	<detailed_description>Most smoker relapse follow smoke cessation treatment . More effective smoking cessation therapy need prevent high rate relapse . Selegiline selective inhibitor monoamine oxidase B ( MAO B ) use clinically combination levodopa treat Parkinson 's disease . Selegiline permit stabilization dopamine ( DA ) level brain prevent rapid degradation DA mean MAO B use adjunct levodopa therapy cause dose-sparing effect enhance dopaminergic transmission . Selegiline 's effect MAO B result effect brain DA interesting implication treatment nicotine dependence brain DA system may play key role mediation reward learn behavior . Previous research suggest brain live smoker show 40 % decrease level MAO B relative nonsmoker former smoker . The purpose study examine whether selegiline , administer form skin patch , effective smoking cessation . Participants randomly assign one two treatment : 1 ) transdermal selegiline patch ( STS ) 2 ) placebo . Treatment STS placebo give period 8 week . Participants stratify gender evaluate role gender play moderate smoke cessation treatment . Study visit take place week 30 45 minute , include adverse event monitoring , biochemical verification smoking status , physical exam . Follow-up visit occur Weeks 24 52 determine response treatment .</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<criteria>Smokes great 20 cigarette per day History Parkinson 's disease , high blood pressure , severe liver kidney disease Current substance abuse Mental illness Skin condition could interfere patch use Using antidepressant medication ( e.g. , levodopa/carbidopa , methyldopa , MAO inhibitor ) Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>